Loading...
Market
Will there be changes in CEO or CFO roles at Senti Biosciences by the end of 2025?
3
Resolution / Starting Odds
CEO change • 25%
CFO change • 25%
Both CEO and CFO change • 25%
No change • 25%
Senti Biosciences official announcements or leadership news
Story
Senti Biosciences Reports Positive SENTI-202 Trial Data, Secures $37.6M Financing, and Sees 139.8% Stock Increase
Dec 2, 2024, 01:20 PM
Senti Biosciences, Inc. announced positive initial clinical data from its Phase 1 trial of SENTI-202, a logic-gated, selective CD33/FLT3-targeting CAR-NK cell therapy for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The trial showed promising results, with two out of three patients achieving minimal residual disease (MRD)-negative complete remission (CR) and a generally favorable safety profile. Additionally, the company secured $37.6 million in an oversubscribed private placement equity financing and appointed Fran Schulz to its Board of Directors as a new member and audit chair. These developments have led to a significant pre-market stock price increase of 139.8%.
View original story
Similar markets
CEO steps down • 25%
CFO steps down • 25%
Both step down • 25%
No change • 25%
CEO replaced • 25%
CFO replaced • 25%
Both CEO and CFO replaced • 25%
No changes in executive leadership • 25%
CEO step down • 25%
CFO step down • 25%
COO step down • 25%
No change • 25%
Anne Wojcicki remains CEO • 25%
New CEO appointed from internal candidate • 25%
New CEO appointed from external candidate • 25%
Interim CEO appointed • 25%
Joanne Kotz remains CEO • 25%
New CEO appointed from Otsuka • 25%
New CEO appointed externally • 25%
Other leadership changes • 25%
CEO steps down • 25%
Other executive changes • 25%
No leadership changes • 25%
Board changes • 25%
Internal promotion • 25%
External hire • 25%
No new CEO appointed • 25%
Anne Wojcicki remains CEO • 25%
New CEO appointed from within the company • 25%
New CEO appointed from outside the company • 25%
Interim CEO appointed • 25%
CEO resignation • 25%
Other executive resignations • 25%
No changes • 25%
Board of Directors changes • 25%
New CFO • 25%
New CEO • 25%
New CTO • 25%
Other • 25%